Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
NeoImmuneTech
University of Michigan Rogel Cancer Center
AbbVie
Shattuck Labs, Inc.
I-Mab Biopharma US Limited
Beth Israel Deaconess Medical Center
Transgene
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Corcept Therapeutics
Merck Sharp & Dohme LLC
Elicio Therapeutics
Institut Bergonié
National Cancer Institute (NCI)
Incyte Corporation
Palleon Pharmaceuticals, Inc.
Incyte Corporation
Incyte Corporation
Sichuan Enray Pharmaceutical Sciences Company
Leap Therapeutics, Inc.
Tesaro, Inc.
Tesaro, Inc.
Institut Bergonié
University of Kentucky
Universitaire Ziekenhuizen KU Leuven
NGM Biopharmaceuticals, Inc
Rutgers, The State University of New Jersey
University of Pennsylvania
National Institutes of Health Clinical Center (CC)
University of West Attica
Aprea Therapeutics
Aprea Therapeutics
Boehringer Ingelheim
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Shattuck Labs, Inc.
Stanford University
Imperial College London
Mario Negri Institute for Pharmacological Research
North Eastern German Society of Gynaecological Oncology
Mayo Clinic
Roswell Park Cancer Institute
Sellas Life Sciences Group
North Eastern German Society of Gynaecological Oncology
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoffmann-La Roche
Emory University